Parminder Singh, MD
Hematology & Oncology · Scottsdale, AZNPI 1194961763
Payments from drug & device makers
Across 442 payments — averaging $22,003 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$7.1M
- Exelixis Inc.$1.1M
- Merck$690K
- Seagen Inc.$571K
- EMD Serono, Inc.$154K
- Pfizer$25K
- plus $45K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 51 | $7,119,697 |
| Exelixis Inc. | 162 | $1,120,737 |
| Merck | 52 | $690,367 |
| Seagen Inc. | 106 | $570,643 |
| EMD Serono, Inc. | 3 | $153,564 |
| Pfizer | 10 | $25,216 |
| Amgen | 5 | $16,547 |
| Novartis | 1 | $7,274 |
| Genentech USA, Inc. | 5 | $4,491 |
| Johnson & Johnson | 6 | $4,463 |
| Bayer | 3 | $2,942 |
| AVEO Pharmaceuticals, Inc. | 6 | $2,703 |
| Astellas Pharma US Inc | 1 | $2,200 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,014 |
| Gilead | 4 | $1,128 |
| Daiichi Sankyo Inc. | 1 | $360 |
| Tempus AI, Inc | 2 | $209 |
| Abbott | 2 | $208 |
| Telix Pharmaceuticals | 1 | $146 |
| Globus Medical | 1 | $140 |
| Amarin Pharma, Inc. | 6 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $72 |
| Abiomed | 2 | $54 |
| Sumitomo Pharma America, Inc. | 1 | $50 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Avanos Medical | 1 | $14 |
How this compares
$9,725,380 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Saurabh ChhabraScottsdale$6.5M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
- Christopher DisimoneScottsdale$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.